Shenzhen YHLO Biotech (688575) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached RMB 887.96 million, up 9.84% year-over-year, driven by domestic demand recovery and international growth.

• Net profit attributable to shareholders was RMB 70.13 million, a 166.97% increase year-over-year, with adjusted net profit (excluding non-recurring items) up 46.81%.

• Operating cash flow improved significantly to RMB 203.16 million from a negative outflow last year.

• Gross margin and profitability improved due to product mix optimization and cost control.

Financial highlights

• Operating income: RMB 887.96 million (+9.84% YoY).

• Net profit: RMB 70.13 million (+166.97% YoY).

• Operating cash flow: RMB 203.16 million (vs. -2.37 million YoY).

• Basic and diluted EPS: RMB 0.12 (+140% YoY).

• Gross margin for self-produced products: 68.73% (+0.68pp YoY).

Outlook and guidance

• Management expects continued growth in both domestic and international markets, with focus on expanding product lines and increasing market penetration.

• R&D investment remains a priority to drive innovation and maintain competitive advantage.